Goldman Sachs
DTIL icon

Goldman Sachs’s Precision BioSciences DTIL Stock Holding History

Goldman Sachs’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$219K Buy
+39,752
New +$183K ﹤0.01% 6044
2025
Q1 		– Sell
-302,168
Closed -$1.15M – 6138
2024
Q4 		$1.15M Buy
302,168
+285,862
+1,753% +$2.09M ﹤0.01% 4715
2024
Q3 		$146K Buy
16,306
+532
+3% +$5.12K ﹤0.01% 5521
2024
Q2 		$153K Buy
+15,774
New +$186K ﹤0.01% 5326
2024
Q1 		– Sell
-16,457
Closed -$180K – 5617
2023
Q4 		$180K Buy
16,457
+655
+4% +$7.06K ﹤0.01% 5187
2023
Q3 		$162K Buy
15,802
+10,278
+186% +$158K ﹤0.01% 5095
2023
Q2 		$87.2K Buy
5,524
+1,655
+43% +$37.8K ﹤0.01% 5381
2023
Q1 		$87.5K Buy
3,869
+1,120
+41% +$36.9K ﹤0.01% 5476
2022
Q4 		$98.1K Sell
2,749
-3,203
-54% -$127K ﹤0.01% 5483
2022
Q3 		$232K Sell
5,952
-4,903
-45% -$233K ﹤0.01% 5416
2022
Q2 		$521K Sell
10,855
-27,159
-71% -$1.59M ﹤0.01% 5053
2022
Q1 		$3.51M Buy
38,014
+5,851
+18% +$795K ﹤0.01% 3687
2021
Q4 		$7.14M Buy
32,163
+10,181
+46% +$2.84M ﹤0.01% 3078
2021
Q3 		$7.61M Buy
21,982
+13,141
+149% +$4.45M ﹤0.01% 2983
2021
Q2 		$3.32M Buy
8,841
+6,525
+282% +$1.96M ﹤0.01% 3721
2021
Q1 		$720K Sell
2,316
-210
-8% -$73.5K ﹤0.01% 4858
2020
Q4 		$632K Sell
2,526
-398
-14% -$97.5K ﹤0.01% 4473
2020
Q3 		$540K Sell
2,924
-1,492
-34% -$297K ﹤0.01% 4447
2020
Q2 		$1.1M Buy
4,416
+3,305
+297% +$724K ﹤0.01% 3878
2020
Q1 		$201K Sell
1,111
-1,921
-63% -$503K ﹤0.01% 4702
2019
Q4 		$1.26M Buy
3,032
+2,319
+325% +$729K ﹤0.01% 3967
2019
Q3 		$180K Buy
713
+27
+4% +$8.79K ﹤0.01% 4847
2019
Q2 		$273K Sell
686
-2,513
-79% -$1.01M ﹤0.01% 4657
2019
Q1 		$1.72M Buy
+3,199
New +$1.7M ﹤0.01% 3735

Other funds holding DTIL

OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Goldman Sachs's DTIL Position: Q1 2026 in Review

Goldman Sachs opened a new position in Precision BioSciences (DTIL) in Q1 2026: 39,752 shares worth $219K. The stake represents ﹤0.01% of the portfolio and ranks #6044 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in DTIL as recently as Q4 2024.

Goldman Sachs first reported a position in DTIL in Q1 2019 and has held it in 24 quarters since. The position peaked at $7.61M in Q3 2021. 78 funds tracked by Wall St. Rank hold DTIL as of Q1 2026.

  • Goldman Sachs held 39,752 shares of Precision BioSciences worth $219K as of Q1 2026.
  • Precision BioSciences was a new Goldman Sachs position in Q1 2026.
  • Precision BioSciences made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6044 holding.
  • Goldman Sachs first reported a position in Precision BioSciences in Q1 2019 and has held it in 24 quarters since.
  • Goldman Sachs's Precision BioSciences position peaked at $7.61M in Q3 2021.
  • 78 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.